scholarly journals Interferon lambda-3 polymorphism and response to pegylated interferon in patients with hepatitis D

2015 ◽  
Vol 20 (5) ◽  
pp. 529-533 ◽  
Author(s):  
Zaigham Abbas ◽  
Javed Yakoob ◽  
Muhammad A Umer ◽  
Minaam Abbas ◽  
Saeed Hamid
Keyword(s):  
Pegylated Interferon ◽  
Hepatitis D ◽  
Interferon Lambda ◽  
Interferon Lambda 3

scholarly journals Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha

2021 ◽  
Vol 11 ◽  
Author(s):  
Andréa Marques Vieira da Silva ◽  
Lucia Elena Alvarado-Arnez ◽  
Tamiris Azamor ◽  
Leonardo Ribeiro Batista-Silva ◽  
Thyago Leal-Calvo ◽  
...  
Keyword(s):  
Innate Immunity ◽  
Hepatitis C ◽  
Interferon Alpha ◽  
Pegylated Interferon ◽  
Serum Levels ◽  
Virologic Response ◽  
Nucleotide Polymorphisms ◽  
Pegylated Interferon Alpha ◽  
Interferon Lambda ◽  
Interferon Lambda 3

Sustained virologic response (SVR) in chronic hepatitis C (CHC) treatment denotes that the host genetics controls the immune response and unequivocally contribute to viral clearance or disease severity. In this context, single nucleotide polymorphisms (SNPs) in the locus of interferon lambda 3 and 4 genes (IFNL3/4) have been important genetic markers of responsiveness to CHC as prognostic markers for the pegylated-Interferon-alpha/ribavirin (Peg-IFN-α/RBV). Here, we analyzed 12 SNPs at the IFNL3/4 region in 740 treatment-naïve patients with CHC infected with hepatitis C virus (HCV) genotypes 1, 2, or 3 treated with Peg-IFN-α/RBV. Individually, rs12979860-CC, rs8109886-CC, or rs8099917-TT were predictive markers of SVR, while rs12979860-CC demonstrated the stronger effect. Besides, the genotypic combination of these three predictors’ genotypes, CC/CC/TT, increased the rate of SVR. Serum levels of cytokines and gene expression analysis on the genes IFNL3, IFNL4, IFNA1, and some of the IFN-stimulated genes (ISGs) were measured in a subgroup of 24 treated patients and 24 healthy volunteers. An antagonist effect was highlighted between the expression of IFNL3/4 and IFNA1 mRNA among patients. Besides, a prominent production of the pro-inflammatory chemokines CCL4 and CXCL10 was observed at a 12-week treatment follow-up. Lower serum levels of these chemokines were detected in patients with an rs12979860-CC genotype associated with the better treatment outcome. Also, lower expression levels of the IFI6, IFI16, IRF9 genes were observed among rs12979860-CC individuals. In conclusion, a combination of the genotypes at the IFNL3/4 locus can act as a better marker for the prognosis for virological responses in an admixed Brazilian population presenting the modulating effect over innate immunity and inflammation that are controlling the outcome of the viral infection, but also other infectious diseases. This study is registered on the ClinicalTrials.gov platform (accession number NCT01889849 and NCT01623336).

Pharmacokinetics and Pharmacodynamics of Pegylated Interferon Lambda-1 in Cynomolgus Monkeys

2012 ◽  
Vol 32 (5) ◽  
pp. 198-206 ◽  
Author(s):  
Kelly A. Byrnes-Blake ◽  
Susan Pederson ◽  
Kevin M. Klucher ◽  
Monica Anderson-Haley ◽  
Dennis M. Miller ◽  
...  
Keyword(s):  
Pegylated Interferon ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Cynomolgus Monkeys ◽  
Interferon Lambda

Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation

2017 ◽  
Vol 88 ◽  
pp. 395-402 ◽  
Author(s):  
Yuke Yan ◽  
Liang Wang ◽  
Jingjing He ◽  
Pengcheng Liu ◽  
Xi Lv ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Interferon Lambda ◽  
Interferon Lambda 3

scholarly journals Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study

2014 ◽  
Vol 61 (3) ◽  
pp. 430-434 ◽  
Author(s):  
Behzad Hajarizadeh ◽  
Bart Grady ◽  
Kimberly Page ◽  
Arthur Y. Kim ◽  
Barbara H. McGovern ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
People Who Inject Drugs ◽  
Acute Infection ◽  
Hepatitis C Virus Rna ◽  
Interferon Lambda ◽  
Virus Rna ◽  
Interferon Lambda 3 ◽  
Rna Levels

Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C

2014 ◽  
Vol 44 (14) ◽  
pp. E447-E454 ◽  
Author(s):  
Yuko Nagaoki ◽  
Michio Imamura ◽  
Yoshiiku Kawakami ◽  
Hiromi Kan ◽  
Hatsue Fujino ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Interferon Lambda

scholarly journals Clinical significance of interferon lambda-3 (IFNλ3)/interleukin 28B (IL28B) in systemic lupus erythematosus patients

2022 ◽  
Vol 44 (2) ◽  
pp. 121-125
Author(s):  
Fatma H. Abdelraouf ◽  
Manal E.S. Ramadan ◽  
Dina O. Abdulazim ◽  
AliGenena ◽  
Heba M. Selim
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Clinical Significance ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Interleukin 28B ◽  
Interferon Lambda ◽  
Interferon Lambda 3
Sign in / Sign up

Export Citation Format

Share Document